#Japan #Tokyo #AI Drug Discovery #Hitachi #MOLCURE

Accelerating Drug Discovery with AI

Hitachi Ltd. has announced plans to develop a cutting-edge platform dubbed the "Confidential AI Base" aimed at expediting drug discovery through open innovation. This initiative comes in collaboration with MollyCure, a company known for its strengths in AI-driven antibody creation. The platform’s primary goal is to facilitate secure collaborations between pharmaceutical companies and academic institutions, allowing them to share sensitive research data and AI models without exposing confidential information.

Overview of the Confidential AI Base

The Confidential AI Base leverages Hitachi's proprietary information management technologies and domain knowledge in pharmaceuticals, IT, and AI. The platform is designed to enable high-security connections between the secretive research data owned by various stakeholders and the AI models brought by startups. This unique feature will not only promote the application of AI in drug development but also enhance the efficiency of the discovery process.

In collaboration with MOLCURE, Hitachi aims to launch the "Open Innovation (OI) Drug Discovery Base Service" in fiscal 2026. This service will initially focus on antibody development, with plans for expansion into other modalities such as nucleic acids and peptides.

Addressing Industry Challenges

The pharmaceutical industry faces significant challenges—soaring research and development costs, dwindling success rates, and extended development timelines. To address these pressing issues, the global market for AI in drug discovery is projected to grow from $2.34 billion in 2023 to $19.35 billion by 2031, with a compound annual growth rate (CAGR) of 30.2% during the forecast period (2024–2031).

However, there are notable hurdles to overcome in the realm of data management. Currently, conventional practices involve strict non-disclosure agreements (NDAs) and data masking, both of which can inadvertently diminish the accuracy of AI learning due to increased anonymity. Hence, creating a secure yet collaborative environment remains a key priority for all stakeholders in the industry.

Ensuring Confidentiality with Advanced Technologies

Hitachi's advanced information management technology utilizes encrypted databases that function within a Trusted Execution Environment (TEE). This innovative approach allows for secure processing of confidential information, reducing the risks associated with data leaks while facilitating seamless collaborations across various organizations.

By using this method, pharmaceutical companies can bring their proprietary research data together while keeping it secure; they can also engage startups like MOLCURE to leverage their robust AI models in a non-disclosed format.

The Future of Open Innovation in Pharmaceuticals

Hitachi and MOLCURE plan to conduct proof-of-concept (PoC) demonstrations by March to validate the platform's effectiveness. Their collaborative effort will invite partnerships from other pharmaceutical companies, contract development organizations, and biotech firms that aim to utilize AI advancements in drug discovery.

The goal is to foster a collaborative ecosystem that encourages further open innovation across the pharmaceutical industry and academia. Moreover, Hitachi intends to evolve this service into a consortium model, where multiple organizations can develop technologies and create new business ventures collectively.

Showcasing Innovations at Upcoming Expo

As part of their promotional efforts, Hitachi will be showcasing this innovative service at the "Pharma IT and Digital Health Expo 2026," scheduled for April 21-23, 2026, at Tokyo Big Sight. Attendees will have the opportunity to learn about Hitachi's confidentiality management technologies and how they are applied within the pharmaceutical sector.

In Conclusion

Hitachi is making significant strides in combining domain expertise with cutting-edge digital technologies to usher in a new era of drug discovery. By integrating artificial intelligence with robust privacy measures, Hitachi and MOLCURE aim not only to enhance the drug development process but also to ensure that sensitive data remains protected.

For further information about this project, please visit the links provided or contact Hitachi and MOLCURE directly.